Mangoceuticals, Inc. (NASDAQ:MGRX – Get Free Report) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 194,400 shares, a growth of 839.1% from the October 15th total of 20,700 shares. Based on an average daily volume of 353,300 shares, the short-interest ratio is presently 0.6 days. Approximately 15.3% of the company’s stock are short sold.
Mangoceuticals Stock Down 0.4 %
NASDAQ MGRX traded down $0.01 on Wednesday, hitting $2.43. 57,573 shares of the stock were exchanged, compared to its average volume of 236,839. Mangoceuticals has a fifty-two week low of $2.10 and a fifty-two week high of $16.80. The company has a market cap of $4.84 million, a PE ratio of -0.38 and a beta of 2.08. The company has a 50-day moving average price of $33.81 and a 200-day moving average price of $60.71.
Mangoceuticals (NASDAQ:MGRX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($20.25) EPS for the quarter. Mangoceuticals had a negative return on equity of 243.34% and a negative net margin of 1,053.93%. The firm had revenue of $0.16 million for the quarter.
Institutional Inflows and Outflows
About Mangoceuticals
Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com.
Recommended Stories
- Five stocks we like better than Mangoceuticals
- 3 Warren Buffett Stocks to Buy Now
- Rocket Lab is the Right Stock for the Right Time
- Investing in Travel Stocks Benefits
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Dividend Payout Ratio Calculator
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Mangoceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mangoceuticals and related companies with MarketBeat.com's FREE daily email newsletter.